Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.62 |
| ▸ | PPARD | Q03181 | 12/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7847075 | 1.00 | FFAR1 (0.62) | FFAR1PPARDMTNR1AMTNR1BHTR6 | |
| SCHEMBL1470461 | 1.00 | FFAR1 (0.62) | FFAR1PPARDMTNR1AMTNR1BHTR6 | |
| SCHEMBL30301824 | 0.90 | FFAR1 (0.52) | FFAR1PPARD | |
| SCHEMBL3590904 | 0.90 | FFAR1 (0.52) | FFAR1PPARD | |
| SCHEMBL3246802 | 0.88 | FFAR1 (0.51) | FFAR1PPARD | |
| SCHEMBL11732903 | 0.86 | MTNR1A (0.49) | FFAR1PPARDMTNR1AMTNR1BHTR6 | |
| SCHEMBL1567606 | 0.86 | MTNR1A (0.51) | FFAR1PPARDMTNR1AMTNR1BHTR6 | |
| SCHEMBL7296740 | 0.84 | MTNR1A (0.50) | FFAR1PPARDMTNR1AMTNR1BHTR6 | |
| SCHEMBL14356155 | 0.84 | MTNR1B (0.50) | FFAR1PPARDMTNR1AMTNR1BHTR6 | |
| SCHEMBL4714587 | 0.84 | HTR6 (0.51) | FFAR1PPARDMTNR1AMTNR1BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-6262060-B1 | TREATMENT OF HYPERGLYCAEMIA, DIABETES, OBESITY OR INFLAMMATION | SANOFI-SYNTHELABO (FR) | 2001-07-17 | — | — | US | disclosed |
| EP-1071666-A1 | AZACYCLOALKANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999052876-A1 | AZACYCLOALKANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | FFAR1 256/4885PPARD 1826/4885MTNR1A 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.